Education
About Us
Working with TipRanks
Follow Us
PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
MDMA Stock Chart & Stats
C$0.11
-C$0.03(-8.33%)
At close: 4:00 PM EST
C$0.11
-C$0.03(-8.33%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.20
Previous CloseN/A
Volume63.47K
Average Volume (3M)208.17K
Market Cap
C$11.43M
Enterprise ValueC$11.35M
Total Cash (Recent Filing)C$857.05K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.87
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding108,887,215
10 Day Avg. Volume94,242
30 Day Avg. Volume208,173
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained TTM revenue growth of +24.6% signals expanding demand for the company's MDMA supply and services within the psychedelic-medicine ecosystem. Over 2-6 months this revenue momentum supports scale-up of operations and improves the odds of reaching positive operating leverage if margins stabilize.
Debt-free Balance SheetA zero-debt capital structure reduces financial risk, lowers fixed financing costs, and gives management flexibility to pursue R&D, regulatory work, or capacity expansion without immediate interest burdens. This conservative financing is a durable buffer during funding cycles.
Cash Losses Aligned With Accounting LossesFree cash flow tracking net income closely implies losses are primarily cash-based rather than driven by volatile non-cash accounting items. That alignment makes future cash planning and financing needs more predictable and reduces short-term accrual risk for lenders and investors.
Bears Say
Negative Gross ProfitA negative gross profit indicates the core manufacturing or product economics are currently unprofitable, meaning unit costs exceed revenues. Unless production efficiency improves or pricing power increases, the company cannot sustainably cover operating expenses, undermining long-term viability.
Ongoing Cash BurnPersistent negative operating and free cash flows mean the business requires external funding to maintain operations. Over a multi-month horizon this raises dilution and refinancing risk, constrains investment in commercialization or R&D, and pressures liquidity if revenues or margins don't improve.
Profitability Deteriorated Vs 2024A step-down from positive gross profit in 2024 to current negative margins signals structural pressures—higher costs, weaker pricing, or lower mix quality. This deterioration evidences business-model stress that must be reversed to secure durable profitability and justify ongoing investment.
PharmAla Biotech Holdings, Inc. News
MDMA FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was C$0.09 and its highest was C$0.20 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is C$11.43M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is May 04, 2026 which is in 49 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 108,887,215 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:MDMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
Technical Analysis
COSCIENS Biopharma
―
Aptose Biosciences
―
Sirona Biochem
―
PreveCeutical Medical
―
PharmaTher Holdings Ltd
―
Options Prices
Currently, No data available
---